ANVS - NYSE
Annovis Bio, Inc.
$2.60
+0.78%Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
At a Glance
Live SnapshotAnnovis Bio, Inc. Management Team
Mr. Mark Patrick Guerin C.M.A., CPA, CFM
Chief Financial Officer
Dr. Maria L. Maccecchini Ph.D.
Founder, Chief Executive Officer, President & Executive Director
Compensation
$748,600
Mr. Blake Jensen M.B.A.
Head of Quality
Ms. Melissa Gaines
Senior Vice President of Clinical Operations
Ms. Eve M. Damiano M.S., RAC
Senior Vice President of Regulatory Operations
Dr. Cheng Fang Ph.D.
Senior Vice President of Research & Development
Ms. Hilda Maibach
Senior Vice President of Statistics
Annovis Bio, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.41M worth of ANVS shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
15.0K
63.60K
0
0.00
+64K
+$64K
6-9 Months
1.1M
2.35M
0
0.00
+2.3M
+$2.35M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Hoffman Michael B
Director
$2.21M
Maccecchini Maria-Luisa
Director, Officer: President & Ceo
$200K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $2.41M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
ANVS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 12, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 15, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 18, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 19, 2021 | June 01, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 24, 2020 | June 03, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.